Mankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337.9 crore compared to ₹3,697.2 crore in the same quarter last year. This growth is attributed to strong performance in both domestic and international markets. The recent acquisition of Armed Cell Therapeutics is expected to enhance R&D capabilities.
Mankind Pharma has announced a profit increase of 37.7% to ₹716 crore during the September quarter. Revenue from operations rose to ₹4,337.9 crore compared to ₹3,697.2 crore in the same quarter last year. This growth is attributed to strong performance in both domestic and international markets. The recent acquisition of Armed Cell Therapeutics is expected to enhance R&D capabilities.
<iframe src="https://hindustansphere.com/embed/cluster/f9293c7c314ea365fcdb0923319586456cd9f7ec" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Mankind Pharma Q2 profit rises 38% to Rs 716 crore"></iframe>
